Session: SUN 281-290-Comparative Effectiveness/Health Outcomes/Quality Improvement/Patient or Provider Education/Endocrine Emergencies
Poster Board SUN-282
Method: Retrospective review of I131 for thyrotoxicosis at Waikato Hospital, NZ during the 3 year period prior to 1 December 2010. Cure was defined as being euthyroid or hypothyroid on replacement at end of follow up, while patients with ongoing Thyroid-Stimulating Hormone (TSH) suppression or those requiring further doses of I131were considered as failure to achieve cure.
Results: A total of 326 doses of I131 were given to 285 patients. Follow up data were available on 283 patients. Median follow-up was 858.5 days (range 30-1525). 83.4% were female. Mean age was 53.12 years (± 14.96) years. Māori comprised 32% of the patients and NZ Europeans 55%. The diagnosis was GD in 61.1% and TMNG in 34.3%. Most patients (98.2%) received a fixed dose of 555mBq (15mCi). At last follow up cure had been achieved in 72.1%. There was no difference in cure rates according to gender (p=0.1212) or diagnosis (GD 70.5% vs TMNG 73.2% p=0.6377). Younger patients (<50 years) were less likely to achieve cure as compared to >50years (63.7% vs 78.6% respectively, p=0.0059). Māori patients were less likely to achieve cure than NZ Europeans (60.4% vs 77.1% respectively, p=0.0058). Māori were also more likely to be younger (49.80 ± 11.29 years vs 55.84 ± 16.04, p=0.0018) and more likely to have a TMNG (47.3% vs 31.2% p=0.0124).
Discussion: A fixed dose of I131 successfully cured hyperthyroidism in 72% of patients treated. In the population studied, age <50 years and Māori ethnicity predicted a lower rate of cure from a single dose of I131 therapy.
Nothing to Disclose: JAT, HMC, JVC, MSE
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters